Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.2K
3.2K
Types of RNA01:20

Types of RNA

8.6K
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
8.6K
Types of RNA01:23

Types of RNA

72.0K
Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
72.0K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

593
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
593
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

250
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
250

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lineage-restricted dependency on an oncofetal SNHG29-IGF2BP1 RNA axis in acute megakaryoblastic leukemia.

Leukemia·2026
Same author

Long Non-coding RNA Based Therapy for Cardiovascular Disease.

Journal of cardiovascular translational research·2025
Same author

An interplay of non-coding RNAs regulates <i>CDH13</i> expression and affects endothelial function and coronary artery disease risk.

Research square·2025
Same author

Aging-regulated PNUTS maintains endothelial barrier function via SEMA3B suppression.

Communications biology·2024
Same author

DLC1 promotes mechanotransductive feedback for YAP via RhoGAP-mediated focal adhesion turnover.

Journal of cell science·2024
Same author

Noncoding RNAs in the Vasculature: Basic Mechanisms and Therapeutic Perspectives.

Arteriosclerosis, thrombosis, and vascular biology·2023
Same journal

The Spectrum of Genetic Causes of Familial Hypercholesterolemia Phenotype.

Current atherosclerosis reports·2026
Same journal

Targeting LDL Across the Whole Spectrum of Chronic Kidney Disease: From Pathophysiology to Novel Treatments.

Current atherosclerosis reports·2026
Same journal

Overview of Novel Mechanisms in Obesity Pharmacotherapy and Implications for Cardiovascular Disease: A Narrative Review.

Current atherosclerosis reports·2026
Same journal

Artificial and Other Non-Nutritive Sweeteners, the Microbiome, and Cardiometabolic Health.

Current atherosclerosis reports·2026
Same journal

Single-cell Technologies in Atherosclerosis: Uncovering Cellular Heterogeneity, Mechanisms, and Therapeutic Opportunities.

Current atherosclerosis reports·2026
Same journal

Primary Prevention of Dyslipidemia: 10 Practice-Changing Takeaways from the 2026 ACC/AHA Multisociety Guideline.

Current atherosclerosis reports·2026
See all related articles

Related Experiment Video

Updated: Dec 12, 2025

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.6K

The Long Non-coding Road to Atherosclerosis.

Tatjana Josefs1, Reinier A Boon2,3,4

  • 1Department of Physiology, Amsterdam Cardiovascular Science, VU University, Amsterdam UMC, Postbus 7057, 1007 MB, Amsterdam, The Netherlands.

Current Atherosclerosis Reports
|August 11, 2020
PubMed
Summary
This summary is machine-generated.

Long non-coding RNAs (lncRNAs) regulate atherosclerosis by influencing cellular processes and plaque development. Further research into these crucial molecules may unlock new therapeutic strategies for cardiovascular diseases (CVD).

Keywords:
AtherosclerosisCardiovascular diseaselncRNA

More Related Videos

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium
11:00

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium

Published on: June 22, 2010

29.4K
RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA
09:36

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA

Published on: April 10, 2018

26.0K

Related Experiment Videos

Last Updated: Dec 12, 2025

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.6K
A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium
11:00

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium

Published on: June 22, 2010

29.4K
RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA
09:36

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA

Published on: April 10, 2018

26.0K

Area of Science:

  • Molecular Biology
  • Genetics
  • Cardiovascular Research

Background:

  • Atherosclerosis is a primary pathology of cardiovascular diseases (CVD), the leading cause of global mortality.
  • Identifying novel therapeutic targets for CVD is a critical area of research.

Purpose of the Study:

  • To review recent findings on the role of long non-coding RNAs (lncRNAs) in atherosclerosis.
  • To highlight the potential of lncRNAs as therapeutic targets for CVD.

Main Methods:

  • Literature review of studies investigating lncRNAs in atherosclerosis.
  • Analysis of lncRNA functions in various cell types relevant to atherosclerosis (ECs, VSMCs, macrophages).

Main Results:

  • LncRNAs regulate key processes in atherosclerosis, including cholesterol homeostasis, inflammation, DNA damage, cell death, and VSMC phenotypic switching.
  • Specific lncRNAs (e.g., LASER, LeXis, CHROME, MANTIS, lncRNA-CCL2, MALAT1) are implicated in disease initiation, plaque growth, and stability.
  • Some lncRNAs correlate with statin treatment response and may serve as CVD biomarkers.

Conclusions:

  • LncRNAs represent a promising novel therapeutic target for atherosclerosis and CVD.
  • Despite current research being in its early stages, lncRNAs hold significant potential for clinical translation in treating cardiovascular diseases.